Gujarat Kidney and Super Speciality Fair Value
Gujarat Kidney and Super Speciality (GKSL) average fair value is ₹16.25 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹139.48 (-88.35%), fair value range ₹5.04–₹24.55. See GKSL book value comparison to compare market price against book value per share.
Fair Value Analysis Export
GKSL Fair Value vs Current Price — Valuation Summary
GKSL average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. Examine GKSL Q4 results for recent quarterly revenue, profit and EPS trends.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
GKSL Fair Value Analysis — Data Sources & Coverage
Gujarat Kidney and Super Speciality financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit GKSL stock price BSE.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
GKSL vs Healthcare Services Sector Peers — P/E, P/B & Market Cap
Gujarat Kidney and Super Speciality P/E ratio, P/B ratio and market capitalisation vs Healthcare Services sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Suraksha Diagnostic | SURAKSHA | 40.64 | 5.71 | ₹1,356 |
| One Global Service Provi… | ONEGLOBAL | 13.34 | 8.2 | ₹872 |
| Invicta Diagnostic | INVICTA | 23.99 | 2.21 | ₹107 |
| Apollo Hospitals | APOLLOHOSP | 62.28 | 12.79 | ₹115,322 |
| Abate AS Industries | ABATEAS | 15.33 | 0.95 | ₹164 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.